Physicians' Education Resource® LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.5 Contact Hours.
This activity is funded by PER®.
Release Date: September 29, 2017
Expiration Date: September 29, 2018
Media: Internet - based
Community Practice Connections™: 1st Annual European Congress on Genitourinary Malignancies™ features a summary of clinical evidence guiding best practices in the treatment of patients with genitourinary (GU) cancers, including recent developments with targeted agents and immunotherapy. Interactive clinical vignettes are followed by short video interviews with internationally renowned experts in the management of patients with GU malignancies. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting by medical professionals engaged in the care of patients with renal cell carcinoma, urothelial carcinoma, and prostate cancer.
This activity is funded by PER®.
Instructions for This Activity and Receiving Credit
This educational activity is intended for medical, surgical, and radiation oncologists, as well as other healthcare professionals involved in the treatment and management of patients with GU malignancies. .
At the conclusion of this activity, you should be better prepared to:
Bernard Escudier, MD
Chair, Genitourinary Oncology Committee
Disclosure: Consultant/Avisory Boards: Pfizer, Novartis, Bristol-Myers Squibb, Roche, Exelixis, Ipsen
Prof. Dr. med., Silke Gillessen
EORTC GU Group
St. Gallen, Switzerland
Disclosure: Consultant/Avisory Boards: Advisory Boards (compensated): AAA International, Active Biotech AB IDMC, Astellas Pharma, Bayer, Bristol-Myers Squibb, Clovis, CureVac, Dendreon Corporation, Ferring, GlaxoSmithKline, Innocrin Pharmaceuticals, Janssen-Cilag, MaxiVAX SA, Millennium Pharmaceuticals, Novartis, Pfizer, Orion, Roche, Sanofi Aventis Group; Advisory Boards (uncompensated): Astellas Pharma, Bayer, ESSA Pharma, Nectar, ProteoMediX, Sanofi, Speakers Bureau: Janssen, Novartis (compensated); Amgen, Astellas Pharma, Bayer, Janssen, Sanofi Aventis Group (uncompensated), Other: Patent: Pending patent application for a method for biomarker WO 2009138392 A1
Prof. Nicholas James
Professor of Clinical Oncology
The Medical School University of Birmingham
Birmingham, United Kingdom
Disclosure: Grant/Research Support: Janssen, Clovis Oncology, Novartis, Pfizer, Sanofi-Aventis, Other: Personal Fees: Astellas Pharma, Novartis, Pfizer, Sanofi-Aventis; Non-Financial Support: Astellas Pharma, Clovis Oncology, Novartis, Pfizer, Sanofi-Aventis
Sumanta K. Pal, MD
Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research
Co-director, Kidney Cancer Program
City of hope
Duarte, California, USA
Disclosure: Consultant/Avisory Boards: fizer, Bristol-Myers Squibb, Exelixis, Novartis, Ipsen, GlaxoSmithKline, Astellas Pharma, Medivation, Speakers Bureau: Genentech, Other: Sumanta K. Pal, MD Pfizer, Bristol-Myers Squibb, Exelixis, Novartis, Ipsen, GlaxoSmithKline, Astellas Pharma, Medivation Genentech Travel Support: Bristol-Myers Squibb, Novartis, Merck
The staff of PER® have no relevant financial relationships with commercial interests to disclose.
As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.
Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
March 8, 2018 - March 11, 2018
Miami Beach, FL
MBCC: A Better Way to Stop Pain: Experts Discuss Paths Toward Responsible Postsurgical Pain Management
March 8, 2018
March 10, 2018
SGO: Show Me the Data™: Leveraging Evidence to Optimize Applications of PARP Inhibitor Strategies in Ovarian Cancer
March 24, 2018
New Orleans, LA
Mar 31, 2018